Literature DB >> 15023583

Hippocampal volume, spectroscopy, cognition, and mood in patients receiving corticosteroid therapy.

E Sherwood Brown1, Dixie J Woolston, Alan Frol, Leonardo Bobadilla, David A Khan, Margaret Hanczyc, A John Rush, James Fleckenstein, Evelyn Babcock, C Munro Cullum.   

Abstract

BACKGROUND: Hippocampal volume reduction, declarative memory deficits, and cortisol elevations are reported in persons with major depressive disorder; however, data linking cortisol elevations with hippocampal atrophy are lacking. Prescription corticosteroid-treated patients offer an opportunity to examine corticosteroid effects on hippocampal volume and biochemistry and memory in humans.
METHODS: Seventeen patients on long-term prescription corticosteroid therapy and 15 controls of similar age, gender, ethnicity, education, height, and medical history were assessed with magnetic resonance imaging and proton magnetic resonance spectroscopy, the Rey Auditory Verbal Learning Test, Stroop Color Word Test and other neurocognitive measures, the Hamilton Rating Scale for Depression, Young Mania Rating Scale, and Brief Psychiatric Rating Scale.
RESULTS: Compared with controls, corticosteroid-treated patients had smaller hippocampal volumes and lower N-acetyl aspartate ratios, lower scores on the Rey Auditory Verbal Learning Test and Stroop Color Word Test, and higher Hamilton Rating Scale for Depression and Brief Psychiatric Rating Scale scores.
CONCLUSIONS: Patients receiving chronic corticosteroid therapy have smaller hippocampal volumes, lower N-acetyl aspartate ratios, and declarative memory deficits compared with controls. These findings support the idea that corticosteroid exposure appears to be associated with changes in hippocampal volume and functioning in humans.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15023583     DOI: 10.1016/j.biopsych.2003.09.010

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  60 in total

1.  Effects of lamotrigine on hippocampal activation in corticosteroid-treated patients.

Authors:  E Sherwood Brown; Liam Zaidel; Greg Allen; Roderick McColl; Miguel Vazquez; Wendy K Ringe
Journal:  J Affect Disord       Date:  2010-05-23       Impact factor: 4.839

2.  Differences in regional brain activation patterns assessed by functional magnetic resonance imaging in patients with systemic lupus erythematosus stratified by disease duration.

Authors:  Meggan Mackay; Mathew P Bussa; Cynthia Aranow; Aziz M Uluğ; Bruce T Volpe; Patricio T Huerta; Miklos Argyelan; Arthur Mandel; Joy Hirsch; Betty Diamond; David Eidelberg
Journal:  Mol Med       Date:  2011-09-21       Impact factor: 6.354

Review 3.  New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors.

Authors:  Michael Maes; Zdenĕk Fišar; Miguel Medina; Giovanni Scapagnini; Gabriel Nowak; Michael Berk
Journal:  Inflammopharmacology       Date:  2012-01-24       Impact factor: 4.473

4.  Hippocampal atrophy in systemic lupus erythematosus.

Authors:  S Appenzeller; A D Carnevalle; L M Li; L T L Costallat; F Cendes
Journal:  Ann Rheum Dis       Date:  2006-01-26       Impact factor: 19.103

5.  Elevated cortisol and learning and memory deficits in cocaine dependent individuals: relationship to relapse outcomes.

Authors:  Helen C Fox; Eric D Jackson; Rajita Sinha
Journal:  Psychoneuroendocrinology       Date:  2009-04-16       Impact factor: 4.905

Review 6.  Corticosteroids and Cognition: A Meta-Analysis.

Authors:  Catherine E Prado; Simon F Crowe
Journal:  Neuropsychol Rev       Date:  2019-05-26       Impact factor: 7.444

7.  Amygdala volume in patients receiving chronic corticosteroid therapy.

Authors:  E Sherwood Brown; Dixie J Woolston; Alan B Frol
Journal:  Biol Psychiatry       Date:  2007-11-05       Impact factor: 13.382

8.  A randomized, placebo-controlled proof-of-concept, crossover trial of phenytoin for hydrocortisone-induced declarative memory changes.

Authors:  E Sherwood Brown; Hanzhang Lu; Daren Denniston; Jinsoo Uh; Binu P Thomas; Thomas J Carmody; Richard J Auchus; Ramon Diaz-Arrastia; Carol Tamminga
Journal:  J Affect Disord       Date:  2013-02-28       Impact factor: 4.839

9.  Attenuation of amygdala atrophy with lamotrigine in patients receiving corticosteroid therapy.

Authors:  Shuchi Desai; Sadia Khanani; Mujeeb U Shad; E Sherwood Brown
Journal:  J Clin Psychopharmacol       Date:  2009-06       Impact factor: 3.153

10.  A comparison of clinician-rated neuropsychological and self-rated cognitive assessments in patients with asthma and rheumatologic disorders.

Authors:  Alan B Frol; Aracely Vasquez; Yonatan Getahun; Maria Pacheco; David A Khan; E Sherwood Brown
Journal:  Allergy Asthma Proc       Date:  2013 Mar-Apr       Impact factor: 2.587

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.